BofA/Merrill analyst Bob Hopkins notes that over the last few weeks, he has had the opportunity to conduct extensive diligence on the stroke market and on the competitive technologies coming to challenge Penumbra's market-leading aspiration system. His conversations with stroke-focused physicians from around the world suggest that, in the short-term, the Street may be underestimating the 4-5 new competitors coming to market. While Hopkins does not necessarily think numbers are too high and the long-term outlook remains strong, he believes short-term there is "greater uncertainty." The analyst reiterates a Buy rating and $150 price target on the shares.